{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T20:37:01Z","timestamp":1768682221021,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"vor","delay-in-days":331,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ijpharm.2018.02.032","type":"journal-article","created":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T18:14:22Z","timestamp":1518891262000},"page":"167-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Topical bio(in)equivalence of metronidazole formulations in vivo"],"prefix":"10.1016","volume":"541","author":[{"given":"Thalita Pedon","family":"de Araujo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle Moura","family":"Fittipaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danilo Cesar Galindo","family":"Bedor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maira Ludna","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah F.","family":"Cordery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard H.","family":"Guy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Bego\u00f1a","family":"Delgado-Charro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davi Pereira","family":"de Santana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila Bastos","family":"Leal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2018.02.032_b0005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40262-016-0442-z","article-title":"Open flow microperfusion as a dermal pharmacokinetic approach to evaluate topical bioequivalence","volume":"56","author":"Bodenlenz","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ijpharm.2018.02.032_b0010","first-page":"531","article-title":"Desenvolvimento e avalia\u00e7\u00e3o da estabilidade f\u00edsica de lo\u00e7\u00f5es O\/A contendo filtros solares","volume":"42","author":"Borghetti","year":"2006","journal-title":"Braz. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2018.02.032_b0015","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1208\/s12248-014-9679-3","article-title":"Survey of international regulatory bioequivalence recommendations for approval of generic topical dermatological drug products","volume":"17","author":"Braddy","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.ijpharm.2018.02.032_b0020","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade, Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria, 2011. Resolu\u00e7\u00e3o RDC n\u00b0 37, 03 de agosto de 2011. Disp\u00f5e sobre o Guia para isen\u00e7\u00e3o e substitui\u00e7\u00e3o de estudos de biodisponibilidade relativa\/bioequival\u00eancia e d\u00e1 outras provid\u00eancias. Minist\u00e9rio da Sa\u00fade, Bras\u00edlia (DF), August 03, 2011."},{"key":"10.1016\/j.ijpharm.2018.02.032_b0025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1208\/s12248-012-9411-0","article-title":"Generic development of topical dermatologic products: formulation development, process development, and testing of topical dermatologic products","volume":"15","author":"Chang","year":"2013","journal-title":"AAPS J."},{"key":"10.1016\/j.ijpharm.2018.02.032_b0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijpharm.2017.06.063","article-title":"Topical bioavailability of diclofenac from locally-acting, dermatological formulations","volume":"529","author":"Cordery","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2018.02.032_b0040","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1016\/S0006-3495(96)79460-2","article-title":"Homogeneous transport in a heterogeneous membrane: water diffusion across human stratum corneum in vivo","volume":"71","author":"Kalia","year":"1996","journal-title":"Biophys. J."},{"key":"10.1016\/j.ijpharm.2018.02.032_b0045","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1023\/A:1026474200575","article-title":"Normalization of stratum corneum barrier function and transepidermal water loss in vivo","volume":"17","author":"Kalia","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2018.02.032_b0050","doi-asserted-by":"crossref","first-page":"817","DOI":"10.5897\/AJPP2016.4605","article-title":"Criteria for the bioanalytical method and its application in dermatopharmacokinetic (DPK) study in pig skin (ex vivo) using metronidazole","volume":"10","author":"Melo","year":"2016","journal-title":"Afr. J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijpharm.2018.02.032_b0055","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s11095-008-9742-9","article-title":"Improved bioequivalence assessment of topical dermatological drug products using dermatopharmacokinetics","volume":"26","author":"N\u2019Dri-Stempfer","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2018.02.032_b0060","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s11095-008-9577-4","article-title":"Optimizing metrics for the assessment of bioequivalence between topical drug products","volume":"25","author":"N\u2019Dri-Stempfer","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2018.02.032_b0065","unstructured":"Pershing, L.K., 2001. Bioequivalence assessment of three 0.025% tretinoin gel products: dermatopharmacokinetic vs. clinical trial methods. In: Transcribed Presentation to the Advisory Committee for Pharmaceutical Sciences Meeting, November 29, Center for Drug Evaluation and Research, FDA, Rockville, pp. 31\u201347. Presentation slides available at: <http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/01\/slides\/3804s2_02_Pershing\/index.htm>; transcript of presentation slides available at: <http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/01\/transcripts\/3804t2_01_Morning_Session.pdf>."},{"key":"10.1016\/j.ijpharm.2018.02.032_b0070","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/A:1011941929495","article-title":"Bioequivalence of topical dermatological dosage forms-methods of evaluation of bioequivalence","volume":"15","author":"Shah","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2018.02.032_b0075","series-title":"Approved Drug Products with Therapeutic Equivalence Evaluations (Electronic Orange Book)","author":"US FDA","year":"2007"},{"key":"10.1016\/j.ijpharm.2018.02.032_b0080","unstructured":"US FDA, 1995. Guidance for Industry: Guidance: Topical Dermatologic Corticosteroids: In Vivo Bioequivalence. Office of Generic Drugs, Center for Drug Evaluations and Research. Available from: <https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM070234.pdf> (cited 16.12.17)."},{"key":"10.1016\/j.ijpharm.2018.02.032_b0085","unstructured":"US FDA, 1998. Guidance for Industry: Topical Dermatological Drug Product NDAs and ANDAs \u2013 In Vivo Bioavailability, Bioequivalence, In Vitro Release, and Associated Studies. Available from: <https:\/\/www.fda.gov\/OHRMS\/DOCKETS\/98fr\/3659bg.pdf> (cited 16.12.17)."},{"key":"10.1016\/j.ijpharm.2018.02.032_b0090","unstructured":"US FDA, 2012. Food and Drug Administration. Office of Generic Drugs. Draft Guidance on Acyclovir Ointment. Available from: <http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm296733.pdf> (cited 16.12.17)."},{"key":"10.1016\/j.ijpharm.2018.02.032_b0095","unstructured":"US FDA, 2016. Food and Drug Administration. Office of Generic Drugs. Draft Guidance on Lidocaine Patch. Available from: <https:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm086293.pdf> (cited 16.12.17)."},{"key":"10.1016\/j.ijpharm.2018.02.032_b0100","unstructured":"US FDA, 2017. Food and Drug Administration. Office of Generic Drugs. Draft Guidance on Dapsone. Available from: <https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM428205.pdf> (cited 16.12.17)."},{"key":"10.1016\/j.ijpharm.2018.02.032_b0105","unstructured":"US FDA, 2017. Food and Drug Administration. Office of Generic Drugs. Draft Guidance on Ivermectin Cream Topical. Available from: <https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM573031.pdf> (cited 16.12.17)."},{"key":"10.1016\/j.ijpharm.2018.02.032_b0110","unstructured":"Wagner, N., 2013. Practical applications to evaluate topical drug products in patients. In: Product Quality Research Institute (PQRI) Workshop on Evaluation of New and Generic Topical Drug Products \u2013 Current Challenges in Bioequivalence, Quality, and Novel Assessment Technologies, Rockville, MD, March 11\u201313, 2013."},{"key":"10.1016\/j.ijpharm.2018.02.032_b0115","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s11095-013-1259-1","article-title":"Current challenges in bioequivalence, quality, and novel assessment technologies for topical products","volume":"31","author":"Yacobi","year":"2014","journal-title":"Pharm. Res."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517318301133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517318301133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T06:23:53Z","timestamp":1566455033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517318301133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":22,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0378517318301133"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2018.02.032","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical bio(in)equivalence of metronidazole formulations in vivo","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2018.02.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V.","name":"copyright","label":"Copyright"}]}}